Sensei Biotherapeutics (FTH) Stock Price, News & Analysis

Company Overview

Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses. These candidates have been evaluated in clinical development for solid tumors, either as standalone treatments or in combination with other immunotherapies.

Sensei Biotherapeutics is headquartered in the United States and has focused its research and clinical-development activities on oncology applications. The company’s publicly reported Nasdaq ticker has been SNSE; FTH does not appear to correspond to Sensei Biotherapeutics. Leadership and pipeline status may change as the company advances or reprioritizes its development programs.

Key Stats

• Today's Range: $18.29 to $21.00
• 50-Day Range: $20.00 to $40.05
• 52-Week Range: $7.45 to $42.14
• Volume: 260,704 shs
• Average Volume: 242,681 shs
• Market Capitalization: $482.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.25
• Consensus Rating: Moderate Buy

Sensei Biotherapeutics Stock Analysis - MarketRank™

Sensei Biotherapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 473rd out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 12 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Sensei Biotherapeutics has a consensus price target of $56.25, representing about 191.4% upside from its current price of $19.30.

Amount of Analyst Coverage

Sensei Biotherapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($13.69) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sensei Biotherapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sensei Biotherapeutics is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sensei Biotherapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.60% of the float of Sensei Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Sensei Biotherapeutics has a short interest ratio ("days to cover") of 3.63, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sensei Biotherapeutics has recently increased by 56.76%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sensei Biotherapeutics does not currently pay a dividend.

Dividend Growth

Sensei Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

Sensei Biotherapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Sensei Biotherapeutics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for FTH on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sensei Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.00% of the stock of Sensei Biotherapeutics is held by insiders.

Percentage Held by Institutions

10.50% of the stock of Sensei Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:FTH
• Previous Symbol: NASDAQ:SNSE
• CIK: 1829802
• Web: www.faeththerapeutics.com
• Phone: (512) 200-2982
• Fax: N/A
• Employees: 29
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Sensei Biotherapeutics: $56.25
• High Price Target: $70.00
• Low Price Target: $50.00
• Potential Upside/Downside: +203.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($141.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,012.17%
• Return on Assets: -175.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.69
• Quick Ratio: 19.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.74 per share
• Price / Book: 1.26

Miscellaneous

• Outstanding Shares: 25,840,000
• Free Float: 24,031,000
• Market Cap: $479.36 million
• Optionable: Not Optionable
• Beta: -0.29